Stacie Weninger

Aratome, LLC specializes in advanced DNA-amplified multiplex immunofluorescence technology that enhances signal detection beyond conventional methods. The private company is based in Menlo Park. The American company ’ s patented approach uses DNA-tagged primary antibodies and cyclical, exponential amplification with branched fluorescent DNA structures to produce bright, stable, and controllable signals. This system supports multiplex staining with distinct oligo sets per channel, enabling simultaneous imaging of multiple antibodies regardless of species, and allows multiple rounds of staining with gentle fluorescent DNA removal. The technology is compatible with standard fluorescence microscopes and typical immunohistochemistry workflows, and is applicable to immunohistochemistry, immunocytochemistry, flow cytometry, western blots, bead assays, ELISA, and in situ hybridization. Aratome offers licensing opportunities for this technology across various research and clinical applications.

Develops disease-modifying therapies to improve the lives of people by neurodegenerative, cardiorenal and other diseases

Develops detect presymptomatic cognitive impairment and aid in tracking cognitive devices

Develops RNA interference based therapeutics to treat neurodegenerative diseases

F-Prime invests in companies located in Asia, Europe, North America and South America. The firm targets companies operating in the fields of life sciences, technology, healthtech & services and crypto sectors. It provides financing for seed, early and later stage transactions.

Manufactures pharmaceutical products